Search
electroCore, Inc.
ECORAdd to Watchlist
8.155USD
-0.145-1.75%
Market hours （ET）Quotes delayed by 15 min
65.28MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.75%
5 Days
+7.73%
1 Month
-21.21%
6 Months
+81.83%
Year to Date
+81.83%
1 Year
+55.63%
Key Figures
8.390Open
8.840High
17.25KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.22%Turnover Ratio
8.300Prev. Close
7.905Low
59.50KTurnover
LossP/E Static
-38.20P/B
0.00%Div Yield TTM
-97.59%ROA
9.68052wk High
0.50Volume Ratio
-11.89MNet Profit
8.00MShares
-1.7700EPS TTM
0.79Beta
-478.70%ROE
4.16052wk Low
11.27%Amplitude
87.27%Gross Margin
65.28MMarket Cap
-2.27Reward/Risk
5.37%Risk Rate
TradingKey Stock Score of electroCore, Inc.
Currency: USD Updated: 2026-07-01Key Insights
electroCore, Inc.'s fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.17.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
electroCore, Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
electroCore, Inc. Highlights
StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 99.83% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.03M.
Undervalued
The company’s latest PE is -4.69, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 923.46K shares, decreasing 26.43% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
19.170
Target Price
+121.88%
Upside Space
electroCore, Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
electroCore, Inc. Info
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Ticker SymbolECOR
CompanyelectroCore, Inc.
CEOGoldberger (Daniel S)
Websitehttps://www.electrocore.com/
Related Instruments
+0.20%
+2.62%
+2.99%
+4.85%
+2.18%
-0.46%
+4.04%
+3.74%
+0.59%
+5.02%
+2.17%
+5.64%
+1.21%
+2.14%
-1.75%
+2.61%
+2.62%
-0.41%
-0.10%
-0.47%Popular Instruments
52626.900
+372.600 (+0.71%)
29277.300
-522.000 (-1.75%)
7457.000
-18.500 (-0.25%)
14751.000
-604.000 (-3.93%)
67954.000
-1531.000 (-2.20%)
6349.500
+74.100 (+1.18%)
67.964
-0.004 (-0.01%)
307.285
+12.905 (+4.38%)
194.315
-3.265 (-1.65%)
4105.950
+75.180 (+1.86%)
FAQs
What is the current price of electroCore, Inc. (ECOR)?
The current price of electroCore, Inc. (ECOR) is 8.30.
What is the symbol of electroCore, Inc.?
The ticker symbol of electroCore, Inc. is ECOR.
What is the 52-week high of electroCore, Inc.?
The 52-week high of electroCore, Inc. is 9.68.
What is the 52-week low of electroCore, Inc.?
The 52-week low of electroCore, Inc. is 4.16.
What is the market capitalization of electroCore, Inc.?
The market capitalization of electroCore, Inc. is 68.85M.
Is electroCore, Inc. (ECOR) currently rated as Buy, Hold, or Sell?
According to analysts, electroCore, Inc. (ECOR) has an overall rating of Buy, with a price target of 19.17.
What is the Earnings Per Share (EPS TTM) of electroCore, Inc. (ECOR)?
The Earnings Per Share (EPS TTM) of electroCore, Inc. (ECOR) is -1.65.